Additionally we have sought whether a biomarker panel based on TLR-induced IL-1β production by PBMCs can distinguish pain from non-pain states in two separate clinical pain populations (medication overuse headache and sciatica) to explore potential clinical utility. This evidence concerns the gene IL1B and Sciatica.